| IOVANCE BIOTHERAPEUTICS |
| USA |
| Gesundheit |
| US4622601007 / A2DT49 |
| 2LB (Frankfurt) / IOVA (NASDAQ) |
| FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA |
| - |
| https://www.iovance.com/ |
|
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The company's approach harnesses the..
>Volltext.. |
| 1670.83 Mio. EUR |
| 1441.34 Mio. EUR |
| 247.63 Mio. EUR |
| -270.04 Mio. EUR |
| -306.87 Mio. EUR |
| -0.82 EUR |
| 41.43 Mio. EUR |
| 170.41 Mio. EUR |
| -234.83 Mio. EUR |
| 2.42 |
| 25.72% |
| 11.73% |
| - |
| - |
| - |
| - |
| IOVANCE |
| 06.08.26 |
|